← Leaderboards
Berenice Yolande Gitomer
University Of Colorado Denver
$3,600,926
Attributed
$7,264,173
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,264,173 · 7
By mechanism
R01$7,001,811 · 5
R21$242,061 · 1
M01$20,301 · 1
Top collaborators
- Michel Benjamin Chonchol13 shared
- Myles S Wolf5 shared
- Jelena Klawitter4 shared
- Petter Bjornstad1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Petter Bjornstad$9,008,713
- Robert W Schrier$16,805,433
- Vijaya M. Vemulakonda$744,399
- Uwe Christians$4,899,838
- Michel Benjamin Chonchol$9,752,858
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectAutosomal Dominant Polycystic KidneyKidneyDisease ProgressionEnd Stage Renal FailureKidney DiseasesRenal FunctionCystHereditary DiseaseLifeResourcesAdultIncidenceUrinaryMagnetic Resonance ImagingGlomerular Filtration RateChildParticipantIndexingInflammationPathogenesisMolecularEventHypertension
Grant awards (22)
Kidney Stone Disease In ADPKD$500,750
R01 · FY2025 · DK
Kidney Stone Disease In ADPKD$491,228
R01 · FY2024 · DK
Kidney Stone Disease In ADPKD$453,195
R01 · FY2023 · DK
Kidney Stone Disease In ADPKD$436,789
R01 · FY2022 · DK
Kidney Stone Disease In ADPKD$471,571
R01 · FY2021 · DK
Measuring metabolically active kidney tissue in autosomal dominant polycystic kidney disease$242,061
R21 · FY2021 · DK
The role of inflammation in the progression of polycystic kidney disease$189,000
R01 · FY2020 · DK
The role of inflammation in the progression of polycystic kidney disease$100,800
R01 · FY2020 · DK
The role of inflammation in the progression of polycystic kidney disease$189,000
R01 · FY2019 · DK
The role of inflammation in the progression of polycystic kidney disease$189,000
R01 · FY2018 · DK
FGF-23 and clinical outcomes in ADPKD patients$344,584
R01 · FY2016 · DK
FGF-23 and clinical outcomes in ADPKD patients$479,326
R01 · FY2015 · DK
Mineralocorticoid Antagonism and Endothelial Dysfunction$337,940
R01 · FY2015 · DK
FGF-23 and clinical outcomes in ADPKD patients$485,928
R01 · FY2014 · DK
Mineralocorticoid Antagonism and Endothelial Dysfunction$336,853
R01 · FY2014 · DK
FGF-23 and clinical outcomes in ADPKD patients$454,586
R01 · FY2013 · DK
Mineralocorticoid Antagonism and Endothelial Dysfunction$335,947
R01 · FY2013 · DK
Dysregulated Angiogenesis in ADPKD$221,468
R01 · FY2013 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$524,846
R01 · FY2012 · DK
Dysregulated Angiogenesis in ADPKD$229,500
R01 · FY2012 · DK · contact PI
Dysregulated Angiogenesis in ADPKD$229,500
R01 · FY2011 · DK · contact PI
GENETIC STUDIES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE$20,301
M01 · FY2007 · RR · contact PI